ArticleInternational journal of nanomedicine2011
Biocompatibility of Fe₃O₄@Au composite magnetic nanoparticles in vitro and in vivo.
Article in International journal of nanomedicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Natural Iron Oxide Nanoparticles Produced by Aquatic Magnetotactic Bacteria as Ideal Nanozymes for Nano-Guided Biosensing Platforms-A Systematic Review.Biosensors · 2025Pooled it
- Long-Term Biodistribution of FeInternational journal of molecular sciences · 2026Article
- Testicular Photohyperthermia Mediated by Magnetic Nanoparticles: Implications for Male Fertility Control.Molecules (Basel, Switzerland) · 2026Article
- Functionalized magnetic hydrogel encapsulation of human dental follicle stem cells under a static magnetic field enhances multi-site bone regeneration.Regenerative biomaterials · 2026Article
- Green-synthesized magnetic core-shell NiFeBiochemistry and biophysics reports · 2025Article
- Iron oxide nanoparticles coated with bioactive materials: a viable theragnostic strategy to improve osteosarcoma treatment.Discover nano · 2025Review
- Research Progress on Using Nanoparticles to Enhance the Efficacy of Drug Therapy for Chronic Mountain Sickness.Pharmaceutics · 2024Review
- Advances in the Optimization of Fe Nanoparticles: Unlocking Antifungal Properties for Biomedical Applications.Pharmaceutics · 2024Review
- A review: hemocompatibility of magnetic nanoparticles and their regenerative medicine, cancer therapy, drug delivery, and bioimaging applications.Frontiers in chemistry · 2023Review
- Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility.Micromachines · 2022Review
- Chitosan/Gamma-Alumina/FeMolecules (Basel, Switzerland) · 2022Article
- Design of Magnetic Nanoplatforms for Cancer Theranostics.Biosensors · 2022Review
- Treatment of tumour tissue with radio-frequency hyperthermia (using antibody-carrying nanoparticles).IET nanobiotechnology · 2021Article
- Magnetic Nanodiscs-A New Promising Tool for Microsurgery of Malignant Neoplasms.Nanomaterials (Basel, Switzerland) · 2021Review
- The Effects of a Varied Gold Shell Thickness on Iron Oxide Nanoparticle Cores in Magnetic Manipulation, TNanomaterials (Basel, Switzerland) · 2020Article
- Biocompatibility of Biomaterials for Nanoencapsulation: Current Approaches.Nanomaterials (Basel, Switzerland) · 2020Review
- Aptamers Increase Biocompatibility and Reduce the Toxicity of Magnetic Nanoparticles Used in Biomedicine.Biomedicines · 2020Review
- Recent Advances in Magnetite Nanoparticle Functionalization for Nanomedicine.Nanomaterials (Basel, Switzerland) · 2019Review
- Small, Smaller, Nano: New Applications for Potato Virus X in Nanotechnology.Frontiers in plant science · 2019Review
- Preparation and Characterization of FeInternational journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis research was conducted to assess the biocompatibility of the core-shell Fe(3)O(4)@ Au composite magnetic nanoparticles (MNPs), which have potential application in tumor hyperthermia.
methodsFe(3)O(4)@Au composite MNPs with core-shell structure were synthesized by reduction of Au(3+) in the presence of Fe(3)O(4)-MNPs prepared by improved co-precipitation. Cytotoxicity assay, hemolysis test, micronucleus (MN) assay, and detection of acute toxicity in mice and beagle dogs were then carried out.
resultsThe result of cytotoxicity assay showed that the toxicity grade of this material on mouse fibroblast cell line (L-929) was classified as grade 1, which belongs to no cytotoxicity. Hemolysis rates showed 0.278%, 0.232%, and 0.197%, far less than 5%, after treatment with different concentrations of Fe(3)O(4)@Au composite MNPs. In the MN assay, there was no significant difference in MN formation rates between the experimental groups and negative control (P > 0.05), but there was a significant difference between the experimental groups and the positive control (P < 0.05). The median lethal dose of the Fe(3)O(4)@Au composite MNPs after intraperitoneal administration in mice was 8.39 g/kg, and the 95% confidence interval was 6.58-10.72 g/kg, suggesting that these nanoparticles have a wide safety margin. Acute toxicity testing in beagle dogs also showed no significant difference in body weight between the treatment groups at 1, 2, 3, and 4 weeks after liver injection and no behavioral changes. Furthermore, blood parameters, autopsy, and histopathological studies in the experimental group showed no significant difference compared with the control group.
conclusionThe results indicate that Fe(3)O(4)@Au composite MNPs appear to be highly biocompatible and safe nanoparticles that are suitable for further application in tumor hyperthermia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.